Navigation Links
Allied Minds Launches Novel Disinfectant/Disinfestant Technology Start-up With UC Davis

Investment Firm, Allied Minds, Establishes New Company to Commercialize

Novel Technology from UC Davis

BOSTON, June 30 /PRNewswire/ -- Allied Minds, a pre-seed investment firm specializing in early stage university business ventures, has established RF Biocidics, Inc., to develop and commercialize a novel disinfectant and disinfestant technology invented at UC Davis.

The newly formed RF Biocidics, Inc. is developing a novel "cleantech" approach using radio frequency (RF) heating to eliminate pathogens and insects without the use of dangerous chemicals or radiation. Traditional efforts to disinfect and disinfest food and agricultural products, have primarily utilized chemical, heat, or radiation inputs with often undesirable results. These methods have inherent problems: 1) toxins are introduced into the food chain and the environment; 2) permanent changes occur in the sensory and nutritional quality of most produce; and 3) radiation drives high the cost of handling and holds a negative consumer perception.

RF heating resolves these issues by delivering lethal energy to insects and microbes without disturbing or damaging the host material or leaving behind any molecules. In general, RF heating eliminates surface heating, reducing thermal loads and allowing a food's quality and nutritional attributes to be maintained. RFB technology is being developed by Professor Manuel Lagunas-Solar of UC Davis.

"We look forward to exploring the many potential applications this technology will encompass. We see benefits in food safety, agriculture, medical sterilization, and as an anti-bioterrorism measure, among others," said Allied Minds COO Marc Eichenberger.

The initial funding for RF Biocidics is being provided by Allied Minds. To learn more about RF Biocidics, please visit .

About Allied Minds, Inc.

Allied Minds is a seed investment company creating partnerships with key universities to fund corporate spinouts resulting from successful early stage technology research. By providing corporate development support as well as finance, Allied Minds aims to guide early stage companies to commercial success, thereby generating value for all stakeholders. For addition information, logon to .

SOURCE Allied Minds, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO
2. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
3. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
4. Glycominds Appoints Board of Directors Chairman
5. Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests
6. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
7. Novozymes Launches Enzyme to Reduce Acrylamide in Food
8. Enova Medical Launches Exos Corporation
9. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
10. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
11. ThirdBiotech Networking Group Launches
Post Your Comments:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology:
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):